These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24608973)

  • 1. Cytotoxic effects of fascaplysin against small cell lung cancer cell lines.
    Hamilton G
    Mar Drugs; 2014 Mar; 12(3):1377-89. PubMed ID: 24608973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines.
    Rath B; Hochmair M; Plangger A; Hamilton G
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30322180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
    Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
    Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
    Tempka D; Tokarz P; Chmielewska K; Kluska M; Pietrzak J; Rygielska Ż; Virág L; Robaszkiewicz A
    Redox Biol; 2018 May; 15():316-326. PubMed ID: 29306194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
    Hamilton G; Klameth L; Rath B; Thalhammer T
    Molecules; 2014 Feb; 19(2):2077-88. PubMed ID: 24549232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4.
    Chen S; Guan X; Wang LL; Li B; Sang XB; Liu Y; Zhao Y
    Gene; 2017 Nov; 635():3-8. PubMed ID: 28888575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product.
    Soni R; Muller L; Furet P; Schoepfer J; Stephan C; Zumstein-Mecker S; Fretz H; Chaudhuri B
    Biochem Biophys Res Commun; 2000 Sep; 275(3):877-84. PubMed ID: 10973815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.
    Plangger A; Rath B; Hochmair M; Funovics M; Neumayer C; Zeillinger R; Hamilton G
    Invest New Drugs; 2022 Apr; 40(2):215-223. PubMed ID: 34596822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan: a review of its efficacy in small cell lung cancer.
    Ormrod D; Spencer CM
    Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
    Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
    J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.
    Huang H; Cao Y; Wei W; Liu W; Lu SY; Chen YB; Wang Y; Yan H; Wu YL
    PLoS One; 2013; 8(6):e66130. PubMed ID: 23762475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
    Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
    Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
    Mahale S; Aubry C; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
    Bioorg Chem; 2006 Oct; 34(5):287-97. PubMed ID: 16904725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
    Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
    Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment.
    Shafer SH; Williams CL
    Int J Oncol; 2003 Aug; 23(2):389-400. PubMed ID: 12851688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells.
    Wasim L; Chopra M
    Cell Oncol (Dordr); 2018 Apr; 41(2):201-212. PubMed ID: 29260509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.